F. Lamoureux, V. Trichet, C. Chipoy, F. Blanchard, F. Gouin et al., Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies, Expert Review of Anticancer Therapy, vol.4, issue.2, pp.169-81, 2007.
DOI : 10.1016/S0140-6736(00)49915-0

P. Picci, Osteosarcoma (osteogenic sarcoma), Orphanet Journal of Rare Diseases, vol.2, issue.1, p.6, 2007.
DOI : 10.1186/1750-1172-2-6

J. Young and F. Hartl, Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23, The EMBO Journal, vol.19, issue.21, pp.5930-5970, 2000.
DOI : 10.1093/emboj/19.21.5930
URL : http://emboj.embopress.org/content/embojnl/19/21/5930.full.pdf

A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M. Boehm et al., A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors, Nature, vol.417, issue.6956, pp.407-417, 2003.
DOI : 10.1038/nature749

G. Chiosis, H. Huezo, N. Rosen, E. Mimnaugh, L. Whitesell et al., 17AAG: low target binding affinity and potent cell activity?finding an explanation, Mol Cancer Ther, vol.2, pp.123-132, 2003.

G. Chiosis, C. Lopes, E. Solit, and D. , Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents, Curr Opin Investig Drugs, vol.7, pp.534-575, 2006.

G. Georgakis and A. Younes, Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond, Future Oncol, vol.1, pp.273-81, 2005.

D. Solit, A. Basso, A. Olshen, H. Scher, and N. Rosen, Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol, Cancer Res, vol.63, pp.2139-2183, 2003.

D. Solit, F. Zheng, M. Drobnjak, P. Munster, B. Higgins et al., 17- Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts, Clin Cancer Res, vol.8, pp.986-93, 2002.

Y. Hu, D. Bobb, J. He, D. Hill, and J. Dome, The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma, Cancer Biology & Therapy, vol.42, issue.6, pp.949-57, 2015.
DOI : 10.1007/s10549-005-9043-5

S. Ambati, E. Lopes, K. Kosugi, U. Mony, A. Zehir et al., Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma, Molecular Oncology, vol.5, issue.2, pp.323-359, 2014.
DOI : 10.1038/nrc1716

P. Mehta, P. Whalen, S. Baxi, P. Kung, S. Yamazaki et al., Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90, Clinical Cancer Research, vol.17, issue.16, pp.5432-5474, 2011.
DOI : 10.1158/1078-0432.CCR-11-0592

A. Myoui, R. Nishimura, P. Williams, T. Hiraga, D. Tamura et al., C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis, Cancer Res, vol.63, pp.5028-5061, 2003.

J. Price, J. Quinn, N. Sims, J. Vieusseux, K. Waldeck et al., The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line, Cancer Research, vol.65, issue.11, pp.4929-4967, 2005.
DOI : 10.1158/0008-5472.CAN-04-4458

A. Yano, S. Tsutsumi, S. Soga, M. Lee, J. Trepel et al., Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone, Proceedings of the National Academy of Sciences, vol.276, issue.5, pp.15541-15547, 2008.
DOI : 10.1074/jbc.M006864200

D. Heymann, B. Ory, F. Gouin, J. Green, and F. Redini, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-380, 2004.
DOI : 10.1016/j.molmed.2004.05.007

M. Rogers, New Insights Into the Molecular Mechanisms of Action of Bisphosphonates, Current Pharmaceutical Design, vol.9, issue.32, pp.2643-58, 2003.
DOI : 10.2174/1381612033453640

R. Russell, Bisphosphonates: Mode of Action and Pharmacology, Pediatrics, vol.119, issue.Supplement 2, pp.150-62, 2007.
DOI : 10.1542/peds.2006-2023H
URL : http://pediatrics.aappublications.org/content/pediatrics/119/Supplement_2/S150.full.pdf

R. Coleman, Risks and benefits of bisphosphonates, British Journal of Cancer, vol.2, issue.11, pp.1736-1776, 2008.
DOI : 10.1093/jnci/djm025
URL : http://www.nature.com/bjc/journal/v98/n11/pdf/6604382a.pdf

D. Heymann, B. Ory, F. Blanchard, M. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

T. Chou and P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Advances in Enzyme Regulation, vol.22, pp.27-55, 1984.
DOI : 10.1016/0065-2571(84)90007-4

F. Lamoureux, M. Baud-'huin, R. Calleja, L. Jacques, C. Berreur et al., Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle, Nature Communications, vol.128, p.3511, 2014.
DOI : 10.1002/ijc.25776

F. Lamoureux, C. Thomas, M. Yin, H. Kuruma, E. Beraldi et al., Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer, Cancer Research, vol.71, issue.17, pp.5838-5887, 2011.
DOI : 10.1158/0008-5472.CAN-11-0994

F. Lamoureux, C. Thomas, M. Yin, H. Kuruma, L. Fazli et al., A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis, Clinical Cancer Research, vol.17, issue.8, pp.2301-2314, 2011.
DOI : 10.1158/1078-0432.CCR-10-3077
URL : http://clincancerres.aacrjournals.org/content/clincanres/17/8/2301.full.pdf

D. Heymann and F. Redini, Targeted therapies for bone sarcomas, BoneKEy Reports, vol.2, p.378, 2013.
DOI : 10.1038/bonekey.2013.112
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817966/pdf

R. Bagatell, J. Beliakoff, C. David, M. Marron, and L. Whitesell, Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin, International Journal of Cancer, vol.103, issue.2, pp.179-88, 2005.
DOI : 10.1128/MCB.16.10.5839

D. Chinn, W. Holland, J. Yoon, T. Zwerdling, and P. Mack, Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines, Pediatric Blood & Cancer, vol.47, issue.6, pp.885-90, 2012.
DOI : 10.1002/pbc.20673

Y. Gazitt, V. Kolaparthi, K. Moncada, C. Thomas, and J. Freeman, Targeted therapy of human osteosarcoma with 17AAG or rapamycin: Characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways, International Journal of Oncology
DOI : 10.3892/ijo_00000181

P. Workman, F. Burrows, L. Neckers, and N. Rosen, Drugging the Cancer Chaperone HSP90: Combinatorial Therapeutic Exploitation of Oncogene Addiction and Tumor Stress, Annals of the New York Academy of Sciences, vol.7, issue.1, pp.202-218, 2007.
DOI : 10.1158/1535-7163.MCT-06-0496

J. Fu, D. Koul, J. Yao, S. Wang, Y. Yuan et al., Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor-Initiating Cells, Cancer Research, vol.73, issue.10, pp.3062-74, 2013.
DOI : 10.1158/0008-5472.CAN-12-2033
URL : http://cancerres.aacrjournals.org/content/canres/73/10/3062.full.pdf

T. Yonemoto, S. Tatezaki, T. Ishii, T. Satoh, H. Kimura et al., Prognosis of Osteosarcoma With Pulmonary Metastases at Initial Presentation Is Not Dismal, Clinical Orthopaedics and Related Research, vol.349, pp.194-203, 1998.
DOI : 10.1097/00003086-199804000-00024

N. Seibel, M. Krailo, Z. Chen, J. Healey, P. Breitfeld et al., Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma, Cancer, vol.44, issue.8, pp.1646-53, 2007.
DOI : 10.1007/978-3-642-74621-5_25

R. Ferracini, D. Renzo, M. Scotlandi, K. Baldini, N. Olivero et al., The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit, Oncogene, vol.10, pp.739-788, 1995.

S. Rong, M. Jeffers, J. Resau, I. Tsarfaty, M. Oskarsson et al., Met expression and sarcoma tumorigenicity, Cancer Res, vol.53, pp.5355-60, 1993.

R. Ferracini, P. Angelini, E. Cagliero, A. Linari, M. Martano et al., Met oncogene aberrant expression in canine osteosarcoma, Journal of Orthopaedic Research, vol.270, issue.2, pp.253-259, 2000.
DOI : 10.1016/S0195-5616(96)50012-4
URL : https://iris.unito.it/bitstream/2318/2570/1/ferracini%20j%20ortp%20res%202000.pdf

S. Patane, S. Avnet, N. Coltella, B. Costa, S. Sponza et al., Overexpression Turns Human Primary Osteoblasts into Osteosarcomas, Cancer Research, vol.66, issue.9, pp.4750-4757, 2006.
DOI : 10.1158/0008-5472.CAN-05-4422

H. Fieten, B. Spee, J. Ijzer, M. Kik, L. Penning et al., Expression of Hepatocyte Growth Factor and the Proto-oncogenic Receptor c-Met in Canine Osteosarcoma, Veterinary Pathology, vol.270, issue.5, pp.869-77, 2009.
DOI : 10.1083/jcb.129.5.1177

J. Christensen, R. Schreck, J. Burrows, P. Kuruganti, E. Chan et al., A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo, Cancer Res, vol.63, pp.7345-55, 2003.

B. Himelstein, N. Asada, M. Carlton, and M. Collins, Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma, Medical and Pediatric Oncology, vol.93, issue.6, pp.471-475, 1998.
DOI : 10.1016/S0092-8674(00)81169-1

M. Roomi, T. Kalinovsky, M. Rath, and A. Niedzwiecki, In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors, International Journal of Oncology, vol.44, issue.1, pp.27-34, 2014.
DOI : 10.3892/ijo.2013.2159

J. Wang, S. Cui, X. Zhang, Y. Wu, and H. Tang, High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer, PLoS ONE, vol.6, issue.4, p.62876, 2013.
DOI : 10.1371/journal.pone.0062876.t003

S. Feng, X. Shi, K. Ren, S. Wu, and X. Sun, Focal adhesion kinase is involved in the migration of human osteosarcoma cells, Oncology Letters, vol.9, issue.6, pp.2670-2674, 2015.
DOI : 10.3892/ol.2015.3131

M. Megison, L. Gillory, J. Stewart, H. Nabers, E. Mrozcek-musulman et al., FAK Inhibition Abrogates the Malignant Phenotype in Aggressive Pediatric Renal Tumors, Molecular Cancer Research, vol.12, issue.4, pp.514-540, 2014.
DOI : 10.1158/1541-7786.MCR-13-0505

E. Glaze, A. Lambert, A. Smith, J. Page, W. Johnson et al., Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance, Cancer Chemotherapy and Pharmacology, vol.38, issue.S7, pp.637-684, 2005.
DOI : 10.1007/s00280-005-1000-9

R. Garcia-carbonero, A. Carnero, and L. Paz-ares, Inhibition of HSP90 molecular chaperones: moving into the clinic, The Lancet Oncology, vol.14, issue.9, pp.358-69, 2013.
DOI : 10.1016/S1470-2045(13)70169-4

R. Chai, M. Kouspou, B. Lang, C. Nguyen, A. Van-der-kraan et al., Molecular Stress-inducing Compounds Increase Osteoclast Formation in a Heat Shock Factor 1 Protein-dependent Manner, Journal of Biological Chemistry, vol.29, issue.19, pp.13602-13616, 2014.
DOI : 10.1182/blood-2008-04-151928

F. Lamoureux, M. Baud-'huin, B. Ory, R. Guiho, A. Zoubeidi et al., Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma, Oncotarget, vol.5, pp.7805-7824, 2014.
DOI : 10.1530/boneabs.1.pp137
URL : http://europepmc.org/articles/pmc4202162?pdf=render

F. Lamoureux, C. Thomas, M. Yin, L. Fazli, A. Zoubeidi et al., Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer, European Urology, vol.66, issue.1, pp.145-55, 2014.
DOI : 10.1016/j.eururo.2013.12.019

B. Ory, F. Blanchard, S. Battaglia, F. Gouin, F. Redini et al., Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status, Molecular Pharmacology, vol.71, issue.1, pp.333-376, 2007.
DOI : 10.1124/mol.106.028837

B. Ory, M. Heymann, A. Kamijo, F. Gouin, D. Heymann et al., Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, vol.91, issue.11, pp.2522-2531, 2005.
DOI : 10.1007/978-1-4419-9129-4_10